Glucose‐dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose‐dependent insulinotropic peptide receptor‐overexpressing adipocytes
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Glucose-dependent insulinotropic peptide (GIP) exerts multiple biological effects via the G-protein-coupled receptor GIPR, including glucose-stimulated insulin production and secretion, cell proliferation, and antiapoptosis in pancreatic β-cells. In an obese state, the circulating level of GIP is elevated. GIPR-knockout mice are resistant to high-fat-diet-induced obesity. The rising evidence suggests a potential role of GIP in adipocyte biology and lipid metabolism. In our study, we overexpressed GIPR in 3T3-L1 CAR adipocytes and demonstrated that GIP impaired the physiological functions of adipocytes as a consequence of increased production of inflammatory cytokines and chemokines and phosphorylation of IkB kinase (IKK)-β through activation of the cAMP-PKA pathway. Activation of Jun N-terminal kinase (JNK) pathway was also observed during GIP-induced inflammatory responses in adipocytes. The inhibition of JNK blocked GIP-stimulated secretion of inflammatory cytokines and chemokines, as well as phosphorylation of IKKβ. In addition, GIP-induced inflammatory response increased basal glucose uptake but inhibited insulin-stimulated glucose uptake. Moreover, GIP-induced adipocyte inflammation impaired insulin signaling in adipocytes as demonstrated by a reduction of AKT phosphorylation. Our results suggest that GIP might be one of the stimuli attributable to obesity-induced insulin resistance via the induction of adipocyte inflammation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, the overexpression of GIP-R in 3T3-L1 cells enhanced an increase in Jun N-terminal kinase (JNK), a mitogen-activated protein kinase (MAPK), and IR [118].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [118]
In the citing paper
“Studies on cells confirm that GIP has pro-inflammatory properties.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [118]
Citations
Cites
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760
Self-citationInflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“Since it regulates insulin release and improves physiology of cells (1, 2), GIP is considered a candidate drug for treating T2DM (40, 41).”
BackgroundAssociation analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link
Hotamisligil, G. S., & Spiegelman, B. M. (1994) · Diabetes · doi:10.2337/diab.43.11.1271 · Cited by 1,281
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Self-citationKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 3×
“that blockade of GIP in mice led to resistance to diet-induced obesity and ameliorated insulin resistance (24, 25).”
BackgroundSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Epac: Defining a New Mechanism for cAMP Action
Gloerich, M., & Bos, J. L. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105714 · Cited by 473
Fineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D., & Baron, A. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353
Kaneto, H., Xu, G., Fujii, N., Kim, S., Bonner-Weir, S., & Weir, G. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202066200 · Cited by 349
Self-citationMcClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2007 · Cited by 239
Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo.
Semb, H., Peterson, J., Tavernier, J., & Olivecrona, T. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47576-x · Cited by 238
Functional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237
Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diab.28.12.1141 · Cited by 219 · cited 1×
“GIP has also been shown to stimulate LPL activity in cultured preadipocytes (29), which have much lower GIPR expression level than differentiated adipocytes (26, 30).”
BackgroundActivation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609088200 · Cited by 216
Adipocyte CREB Promotes Insulin Resistance in Obesity
Qi, L., Saberi, M., Zmuda, E., Wang, Y., Altarejos, J., Zhang, X., Dentin, R., Hedrick, S., Bandyopadhyay, G., Hai, T., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.01.006 · Cited by 190
KAWAKAMI, M., MURASE, T., OGAMA, H., ISHIBASHI, S., MORI, N., TAKAKU, F., & SHIBATA, S. (1987) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a121917 · Cited by 183
Ruan, H., Zarnowski, M. J., Cushman, S. W., & Lodish, H. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305257200 · Cited by 168
Obesity-Related Upregulation of Monocyte Chemotactic Factors in Adipocytes
Jiao, P., Chen, Q., Shah, S., Du, J., Tao, B., Tzameli, I., Yan, W., & Xu, H. (2009) · Diabetes · doi:10.2337/db07-1344 · Cited by 166
Self-citationEffect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.
Wasada, T., McCorkle, K., Harris, V, Kawai, K., Howard, B., & Unger, R. H. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110335 · Cited by 153
Song, D. H., Getty–Kaushik, L., Tseng, E., Simon, J., Corkey, B. E., & Wolfe, M. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.005 · Cited by 137 · cited 1×
“In addition, GIP enhances Glut-4 membrane accumulation and glucose uptake via activation of AKT in 3T3-L1 adipocytes (31).”
BackgroundKim, S.-J., Nian, C., & McIntosh, C. H. S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006841 · Cited by 133
Egan, J. M. (1994) · Endocrinology · doi:10.1210/en.135.5.2070 · Cited by 121
Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumour necrosis factor
Cornelius, P., Enerback, S., Bjursell, G., Olivecrona, T., & Pekala, P. H. (1988) · Biochemical Journal · doi:10.1042/bj2490765 · Cited by 119
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704896200 · Cited by 118 · cited 1×
“One possible explanation is the activity of lipoprotein lipase (LPL), an enzyme that hydrolyzes TG to free fatty acid (FFA) for uptake by adipocytes for reesterification and long-term storage of TG, is increased in adipocytes, and this effect is enhanced by GIP in the presence of insulin (18, 19).”
BackgroundBailey, C. J., Flatt, P. R., Kwasowski, P., Powell, C. J., & Marks, V. (1986) · Acta Endocrinologica · doi:10.1530/acta.0.1120224 · Cited by 116
Effect of GLP-1 on lipid metabolism in human adipocytes
Villanueva-Peñacarrillo, M. L., Márquez, L., González, N., Díaz-Miguel*, M., & Valverde, I. (2001) · Hormone and Metabolic Research · doi:10.1055/s-2001-12428 · Cited by 113
Green, B., Gault, V., O'Harte, F., & Flatt, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043382774 · Cited by 111 · cited 10×
“Abbreviations: aP2, fatty acid binding protein 4; ATGL, adipose triglyceride lipase; CCS, cosmic calf serum; DPP4, dipeptidyl peptidase-4; FAS, fatty acid synthase; FFA, free fatty acid; GFP, green fluorescent protein; GIP, glucose-dependent insulinotropic peptide; GIPR, glucose-dependent insulinotropic peptide recept…”
BackgroundInfluentialKnapper, J. M. E., Puddicombe, S. M., Morgan, L. M., & Fletcher, J. M. (1995) · The Journal of Nutrition · doi:10.1093/jn/125.2.183 · Cited by 109
Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus
Iltz, J. L., Baker, D. E., Setter, S. M., & Campbell, R. K. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.05.006 · Cited by 103
Mottillo, E. P., Shen, X. J., & Granneman, J. G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.04.012 · Cited by 92
Lipolytic action of glucagon-like peptides in isolated rat adipocytes
Ruiz-Grande, C., Alarcón, C., Mérida, E., & Valverde, I. (1992) · Peptides · doi:10.1016/0196-9781(92)90134-o · Cited by 89
Evidence for an abnormal postprandial response to a high-fat meal in women predisposed to obesity
Raben, A., Andersen, H. B., Christensen, N. J., Madsen, J., Holst, J. J., & Astrup, A. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.267.4.e549 · Cited by 89
Siegel, E. G., & Creutzfeldt, W. (1985) · Diabetologia · doi:10.1007/bf00291078 · Cited by 83
Fan, R., Li, X., Gu, X., Chan, J. C. N., & Xu, G. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01238.x · Cited by 82
Self-citationMcIntosh, C. H. S., Bremsak, I., Lynn, F. C., Gill, R., Hinke, S. A., Gelling, R., Nian, C., McKnight, G., Jaspers, S., & Pederson, R. A. (1999) · Endocrinology · doi:10.1210/endo.140.1.6464 · Cited by 73
Sitagliptin: A Novel Drug for the Treatment of Type 2 Diabetes
Choy, M., & Lam, S. (2007) · Cardiology in Review · doi:10.1097/crd.0b013e318123f771 · Cited by 73
Weaver, R. E., Donnelly, D., Wabitsch, M., Grant, P. J., & Balmforth, A. J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.148 · Cited by 63 · cited 1×
“GIP has also been shown to stimulate LPL activity in cultured preadipocytes (29), which have much lower GIPR expression level than differentiated adipocytes (26, 30).”
BackgroundConstruction of stable coxsackievirus and adenovirus receptor-expressing 3T3-L1 cells
Orlicky, D. J., DeGregori, J., & Schaack, J. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31614-x · Cited by 63
Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diabetes.28.12.1141 · Cited by 63
Mohammad, S., Ramos, L. S., Buck, J., Levin, L. R., Rubino, F., & McGraw, T. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.289009 · Cited by 59
Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice
Flatt, P. R., Bailey, C. J., Kwasowski, P., Page, T., & Marks, V. (1984) · Journal of Endocrinology · doi:10.1677/joe.0.1010249 · Cited by 58
Inhibition of actions of glucagon in adipocytes by gastric inhibitory polypeptide
Dupre, J., Greenidge, N., McDonald, T. J., Ross, S. A., & Rubinstein, D. (1976) · Metabolism · doi:10.1016/s0026-0495(76)80002-9 · Cited by 53
Morgan, L. M., Tredger, J. A. T., Hampton, S. M., French, A. P., Peake, J. C. F., & Marks, V. (1988) · British Journal of Nutrition · doi:10.1079/bjn19880073 · Cited by 51
Tchivileva, I. E., Tan, K. S., Gambarian, M., Nackley, A. G., Medvedev, A. V., Romanov, S., Flood, P. M., Maixner, W., Makarov, S. S., & Diatchenko, L. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.008 · Cited by 39
Nie, Y., & Wong, C. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00382.x · Cited by 35
Self-citationIrwin, N., McClean, P. L., Cassidy, R. S., O'Harte, F. P. M., Green, B. D., Gault, V. A., Harriott, P., & Flatt, P. R. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.729 · Cited by 32
Role of gastric inhibitory polypeptide in postprandial hyperinsulinemia of obesity
Roust, L. R., Stesin, M., Go, V. L., O'Brien, P. C., Rizza, R. A., & Service, F. J. (1988) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1988.254.6.e767 · Cited by 16
Cited by
Estrogen deficiency and the origin of obesity during menopause
Lizcano, F., & Guzmán, G. (2014) · BioMed Research International · doi:10.1155/2014/757461 · Cited by 586
Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition
Hameed, I., Masoodi, S. R., Mir, S. A., Nabi, M., Ghazanfar, K., & Ganai, B. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i4.598 · Cited by 506
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity
Donath, M. Y., Dalmas, É., Sauter, N. S., & Böni-Schnetzler, M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.001 · Cited by 338
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Metadata
- Authors
- Nie, Y., Ma, R. C., Chan, J. C. N., Xu, H., & Xu, G.
- Affiliations
- Chinese University of Hong Kong (HK)
- Department of Medicine and Therapeutics Chinese University of Hong Kong Prince of Wales Hospital Hong Kong China
- Brown University (US)
- Corresponding author
- Xu, Gang
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2012-02-24
- Volume
- 26
- Issue
- 6
- Pages
- 2383-2393
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2136968036
- Cited by
- 53
- References
- 55
- Citations by year
- 2026: 3 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 2 · 2017: 3 · 2016: 1 · 2015: 5 · 2014: 10 · 2013: 8 · 2012: 3
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, adipocyte inflammation, insulin resistance, obesity, inflammatory cytokines, chemokines, IκB kinase β, cAMP/PKA signaling, JNK signaling, insulin signaling, Akt phosphorylation, glucose uptake, adipocytes
- MeSH terms
- Animals, Gastric Inhibitory Polypeptide, Glucose, Inflammation, Insulin, Receptors, Gastrointestinal Hormone, Signal Transduction, Gene Expression, Adipocytes, 3T3-L1 Cells, MAP Kinase Kinase 4, Proto-Oncogene Proteins c-akt, Mice, I-kappa B Kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.